US OptionsDetailed Quotes
PLSE240920C20000
- 2.50
- -1.20-32.43%
15min DelayClose Aug 26 16:00 ET
2.50High2.50Low
2.50Open3.70Pre Close25 Volume349 Open Interest20.00Strike Price6.25KTurnover105.46%IV9.60%PremiumSep 20, 2024Expiry Date0.53Intrinsic Value100Multiplier24DDays to Expiry1.97Extrinsic Value100Contract SizeAmericanOptions Type0.5966Delta0.0693Gamma8.21Leverage Ratio-0.0464Theta0.0065Rho4.90Eff Leverage0.0205Vega
Pulse Biosciences Stock Discussion
Sign in to post a comment
$Pulse Biosciences (PLSE.US)$ Reuters· 1 min ago
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study With Its Nano-Pfa Cardiac Surgery System
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study With Its Nano-Pfa Cardiac Surgery System
1
$Pulse Biosciences (PLSE.US)$ Reuters · just 1min. Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for Cellfx® Nspfa Cardiac Surgery System for the Treatment of Atrial Fibrillation
$Pulse Biosciences (PLSE.US)$ Officer Barrett Burke Thomas purchased 10,000 shares of common stock on May 20, 2024 at an average price of $8.56 for a total value of $85,600.
1
$Pulse Biosciences (PLSE.US)$ Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
1 MINUTE AGO, 8:00 AM EST
VIA BUSINESSWIRE![]()
1 MINUTE AGO, 8:00 AM EST
VIA BUSINESSWIRE
$Pulse Biosciences (PLSE.US)$ Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp 1 MINUTE AGO, 8:00 AM EST VIA BUSINESSWIRE![]()
1
$Pulse Biosciences (PLSE.US)$ Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter 3 MINUTES AGO, 8:00 AM EST VIA BUSINESSWIRE![]()
$Pulse Biosciences (PLSE.US)$ 10% Shareholder DUGGAN ROBERT W purchased 218.6K shares of Common Stocks on Nov 29, 2023 at an average price of $9.38 for a total value of $2.05 million![]()
No comment yet
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment